{"classes":[{"categories":[{"measurements":[{"comment":"Data was reported as a one sided Confidence Interval, so there is no upper limit interval reported","groupId":"OG000","lowerLimit":"1.2","upperLimit":"NA","value":"1.4"}]}],"title":"Time to Progression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.17","upperLimit":"14.43","value":"12"}]}],"title":"Overall Survival"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Assessment of time to disease progression and overall survival","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II, Single-Arm, Multi-Site study. All subjects will receive the investigational agent, GC1008 in 3 week cycles of treatment\n\nGC1008: GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.","id":"OG000","title":"Investigational Drug infusion-for Safety and Effectiveness"}],"paramType":"MEDIAN","populationDescription":"Outcome analysis presented in manuscript of results of trial based on 13 participants.","reportingStatus":"POSTED","timeFrame":"18 months","title":"Time to Progression and Overall Survival","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Months"}